Janux Therapeutics, Inc. (NASDAQ:JANX) Receives $78.31 Average PT from Brokerages

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) have been assigned an average rating of “Buy” from the sixteen analysts that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating, thirteen have assigned a buy rating and two have assigned a strong buy rating to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $78.3077.

Several research analysts have recently weighed in on the stock. Barclays assumed coverage on shares of Janux Therapeutics in a report on Wednesday, September 17th. They issued an “overweight” rating and a $47.00 price target on the stock. Piper Sandler started coverage on shares of Janux Therapeutics in a research report on Monday, August 18th. They set an “overweight” rating and a $42.00 target price for the company. Truist Financial started coverage on shares of Janux Therapeutics in a research report on Wednesday, September 10th. They set a “buy” rating and a $100.00 target price for the company. Stifel Nicolaus reiterated a “buy” rating and set a $45.00 target price on shares of Janux Therapeutics in a research report on Wednesday, September 10th. Finally, Guggenheim started coverage on shares of Janux Therapeutics in a research report on Wednesday, September 3rd. They set a “buy” rating and a $72.00 target price for the company.

Janux Therapeutics Price Performance

Shares of JANX stock opened at $23.70 on Monday. The company’s fifty day simple moving average is $23.93 and its two-hundred day simple moving average is $25.68. Janux Therapeutics has a 1 year low of $21.73 and a 1 year high of $71.71. The stock has a market capitalization of $1.42 billion, a price-to-earnings ratio of -13.17 and a beta of 2.82.

Janux Therapeutics (NASDAQ:JANX) last issued its earnings results on Thursday, August 7th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.07). Equities research analysts anticipate that Janux Therapeutics will post -1.38 EPS for the current year.

Hedge Funds Weigh In On Janux Therapeutics

Several institutional investors have recently modified their holdings of JANX. Ameriprise Financial Inc. increased its position in shares of Janux Therapeutics by 182.8% during the 4th quarter. Ameriprise Financial Inc. now owns 14,906 shares of the company’s stock valued at $798,000 after purchasing an additional 9,636 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Janux Therapeutics by 532.7% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 165,737 shares of the company’s stock valued at $8,874,000 after purchasing an additional 139,543 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of Janux Therapeutics during the 4th quarter valued at about $2,477,000. California State Teachers Retirement System increased its position in shares of Janux Therapeutics by 82.2% during the 4th quarter. California State Teachers Retirement System now owns 36,735 shares of the company’s stock valued at $1,967,000 after purchasing an additional 16,575 shares during the last quarter. Finally, Wellington Management Group LLP increased its position in shares of Janux Therapeutics by 3,592.9% during the 4th quarter. Wellington Management Group LLP now owns 535,396 shares of the company’s stock valued at $28,665,000 after purchasing an additional 520,898 shares during the last quarter. 75.39% of the stock is currently owned by institutional investors.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.